Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : wla(warner lambert) -- Ignore unavailable to you. Want to Upgrade?

To: Captain Jack who wrote (398)	1/15/1999 9:36:00 AM
From: Anthony Wong	Respond to of 942

FDA Advisory Committee to Review REZULIN Post-Marketing Data and Supplemental New Drug Application (Company Press Release) Friday January 15, 7:30 am Eastern Time biz.yahoo.com

To: Captain Jack who wrote (398)	1/15/1999 9:43:00 AM
From: Anthony Wong	Read Replies (2) \| Respond to of 942

On 1/14 Everen Securities reiterates 1-1 rating, short term target $88, long term $94 Paine Webber reiterates buy, prescriptions running strong; potential upside to estimates nordby.com

To: Captain Jack who wrote (398)	1/15/1999 9:57:00 AM
From: Anthony Wong	Read Replies (1) \| Respond to of 942

MORRIS PLAINS, N.J. (Dow Jones)--Warner-Lambert Co. (WLA) said the Food and Drug Administration's Endocrinologic and Metabolic Drugs Advisory Committee will review its Rezulin oral therapy for type 2 diabetes. In a press release Friday, the company said the committee plans to review Rezulin's post-marketing safety and efficacy data and Warner-Lambert's supplemental new drug application for combination therapy with both metformin and with sulfonylureas and metformin. The committee will review the items in March. (MORE) DOW JONES NEWS 01-15-99 07:52 AM WLA - NYSE Warner-Lambert said it welcomes a "rational review" of Rezulin in a scientific forum, citing recent inaccurate claims and misstatements based on anecdotal case reports. The company believes the review process will find that the benefits of Rezulin therapy for type 2 diabetes patients "far outweigh the risks." (MORE) DOW JONES NEWS 01-15-99 07:54 AM